Latest Issue

Volume 7 Issue 4

Paper of the Month

Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G et al.
University of Basel, Basel, Switzerland.
Neurology 2015;85:29–39.
Natalizumab and fingolimod are disease-modifying therapies in relapsing–remitting multiple sclerosis (RRMS). Natalizumab treatment can be discontinued because of disease breakthrough, JC virus positivity and thereby the risk of developing progressive multifocal leukoencephalopathy (PML), patient preference for oral therapies, persistent anti-natalizumab antibodies, or poor tolerability.
» Read an expert review of this paper

Webcast

Rehabilitation in multiple sclerosis
Prof Alan Thompson (Director, UCL Institute of Neurology, London, UK) discusses rehabilitation for people with multiple sclerosis.

Latest news

  • Home
  • Home
  • Home
  • Home
  • Home
  • Home

READER POLL

MS Poll 1
Which of the following do you think is the most important risk factor for MS?






Powered by NetPolls

READER SURVEY

SUBMIT AN ARTICLE

OTHER REMEDICA JOURNALS

COMPASS PUBMED SEARCH

Enter your search terms below to search pubmed for articles